Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer
N Tanaka, T Enokida, T Fujisawa, S Okano… - International Journal of …, 2022 - Springer
Abstract Background Cetuximab (Cmab) plays an important role in the treatment for
recurrent or metastatic head and neck cancer (R/M HNC). To date, however, no safety data …
recurrent or metastatic head and neck cancer (R/M HNC). To date, however, no safety data …
[HTML][HTML] Is the scope of costs considered in budget impact analyses for anticancer drugs rational? A systematic review and comparative study
Y Ma, Y Li, A Ma, H Li - Frontiers in Public Health, 2021 - frontiersin.org
Background: With the increasing disease burden of cancer worldwide, more and more
anticancer drugs have been approved in many countries, and the results of budget impact …
anticancer drugs have been approved in many countries, and the results of budget impact …
[HTML][HTML] Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs
Y Ma, J Zhou, Y Ye, A Ma, H Li - Cost Effectiveness and Resource …, 2023 - Springer
Background The duration of treatment (DOT) of the initial intervention and subsequent
treatment is the key to determining the accuracy of anticancer-drug budget impact analysis …
treatment is the key to determining the accuracy of anticancer-drug budget impact analysis …